Name: Targeting Breast Cancer: A Journey from Design to Dynamics (en Inglés)
SKU: 66203909
Price: 1151.35 MXN
Availability: InStock
Author: Belghalia, Etibaria; Sbai, Abdelouahid; Bouachrine, Mohammed
ISBN: 9786207463428

portada Targeting Breast Cancer: A Journey from Design to Dynamics (en Inglés)

Targeting Breast Cancer: A Journey from Design to Dynamics (en Inglés)

Formato

Libro Físico

Editorial

LAP Lambert Academic Publishing

Autor

Belghalia, Etibaria; Sbai, Abdelouahid; Bouachrine, Mohammed

Idioma

Inglés

N° páginas

108

Encuadernación

Tapa Blanda

Dimensiones

22.9x15.2x0.7 cm

ISBN13

9786207463428

Targeting Breast Cancer: A Journey from Design to Dynamics (en Inglés)

Belghalia, Etibaria; Sbai, Abdelouahid; Bouachrine, Mohammed (Autor) · LAP Lambert Academic Publishing · Tapa Blanda

Libro Nuevo Importado

Envío: 23 a 28 días háb.

$ 2,302.70$ 1,151.35

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 10 unidades

$ 1,151.35

¡Envío Gratis! Llega entre el 05 Oct y el 13 Oct a CUAUHTÉMOC, Ciudad de México. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Targeting Breast Cancer: A Journey from Design to Dynamics (en Inglés)"

This book explores the contribution of computational methods in the search for targeted breast cancer therapies. It focuses on three key receptors: estrogen receptor alpha (ERα), human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor (EGFR). Two chemical families, pyrazole-benzimidazole derivatives and Baloxavir analogs, were evaluated through QSAR modeling, molecular docking, ADMET predictions, and molecular dynamics simulations. The first study identified two compounds with strong binding affinity and favorable pharmacokinetic properties. The second revealed several Baloxavir derivatives with promising multi-target activity, including one lead compound showing stable interactions with all three receptors. These results highlight the potential of in silico techniques in early-stage drug discovery and provide a foundation for further biological validation, supporting the development of more effective and personalized treatments for breast cancer.